These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
365 related articles for article (PubMed ID: 12682277)
1. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. Dreier T; Baeuerle PA; Fichtner I; Grün M; Schlereth B; Lorenczewski G; Kufer P; Lutterbüse R; Riethmüller G; Gjorstrup P; Bargou RC J Immunol; 2003 Apr; 170(8):4397-402. PubMed ID: 12682277 [TBL] [Abstract][Full Text] [Related]
2. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA MAbs; 2015; 7(3):584-604. PubMed ID: 25875246 [TBL] [Abstract][Full Text] [Related]
3. Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells. Cochlovius B; Kipriyanov SM; Stassar MJ; Christ O; Schuhmacher J; Strauss G; Moldenhauer G; Little M J Immunol; 2000 Jul; 165(2):888-95. PubMed ID: 10878363 [TBL] [Abstract][Full Text] [Related]
4. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Dreier T; Lorenczewski G; Brandl C; Hoffmann P; Syring U; Hanakam F; Kufer P; Riethmuller G; Bargou R; Baeuerle PA Int J Cancer; 2002 Aug; 100(6):690-7. PubMed ID: 12209608 [TBL] [Abstract][Full Text] [Related]
5. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Schlereth B; Quadt C; Dreier T; Kufer P; Lorenczewski G; Prang N; Brandl C; Lippold S; Cobb K; Brasky K; Leo E; Bargou R; Murthy K; Baeuerle PA Cancer Immunol Immunother; 2006 May; 55(5):503-14. PubMed ID: 16032400 [TBL] [Abstract][Full Text] [Related]
6. Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. Kipriyanov SM; Cochlovius B; Schäfer HJ; Moldenhauer G; Bähre A; Le Gall F; Knackmuss S; Little M J Immunol; 2002 Jul; 169(1):137-44. PubMed ID: 12077238 [TBL] [Abstract][Full Text] [Related]
7. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity. Lefterova P; Märten A; Buttgereit P; Weineck S; Scheffold C; Huhn D; Schmidt-Wolf IG J Immunother; 2000; 23(3):304-10. PubMed ID: 10838659 [TBL] [Abstract][Full Text] [Related]
8. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Löffler A; Kufer P; Lutterbüse R; Zettl F; Daniel PT; Schwenkenbecher JM; Riethmüller G; Dörken B; Bargou RC Blood; 2000 Mar; 95(6):2098-103. PubMed ID: 10706880 [TBL] [Abstract][Full Text] [Related]
9. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975 [TBL] [Abstract][Full Text] [Related]
10. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Moore PA; Zhang W; Rainey GJ; Burke S; Li H; Huang L; Gorlatov S; Veri MC; Aggarwal S; Yang Y; Shah K; Jin L; Zhang S; He L; Zhang T; Ciccarone V; Koenig S; Bonvini E; Johnson S Blood; 2011 Apr; 117(17):4542-51. PubMed ID: 21300981 [TBL] [Abstract][Full Text] [Related]
11. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Hoffmann P; Hofmeister R; Brischwein K; Brandl C; Crommer S; Bargou R; Itin C; Prang N; Baeuerle PA Int J Cancer; 2005 May; 115(1):98-104. PubMed ID: 15688411 [TBL] [Abstract][Full Text] [Related]
12. Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy. Haagen IA Leuk Lymphoma; 1995 Nov; 19(5-6):381-93. PubMed ID: 8590837 [TBL] [Abstract][Full Text] [Related]
13. Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3. Schlereth B; Kleindienst P; Fichtner I; Lorenczewski G; Brischwein K; Lippold S; da Silva A; Locher M; Kischel R; Lutterbüse R; Kufer P; Baeuerle PA Cancer Immunol Immunother; 2006 Jul; 55(7):785-96. PubMed ID: 16187083 [TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan. Zhang X; Yang Y; Zhang L; Lu Y; Zhang Q; Fan D; Zhang Y; Zhang Y; Ye Z; Xiong D J Hematol Oncol; 2017 Feb; 10(1):56. PubMed ID: 28228105 [TBL] [Abstract][Full Text] [Related]
15. Bispecific antibody fragments with CD20 X CD28 specificity allow effective autologous and allogeneic T-cell activation against malignant cells in peripheral blood and bone marrow cultures from patients with B-cell lineage leukemia and lymphoma. Brandl M; Grosse-Hovest L; Holler E; Kolb HJ; Jung G Exp Hematol; 1999 Aug; 27(8):1264-70. PubMed ID: 10428503 [TBL] [Abstract][Full Text] [Related]
16. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978 [TBL] [Abstract][Full Text] [Related]
17. Anti-idiotype x anti-LFA-1 bispecific antibodies inhibit metastasis of B cell lymphoma. Cohen S; Haimovich J; Hollander N J Immunol; 2003 Mar; 170(5):2695-701. PubMed ID: 12594299 [TBL] [Abstract][Full Text] [Related]
19. T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16. Pörtner LM; Schönberg K; Hejazi M; Brünnert D; Neumann F; Galonska L; Reusch U; Little M; Haas R; Uhrberg M Cancer Immunol Immunother; 2012 Oct; 61(10):1869-75. PubMed ID: 22976535 [TBL] [Abstract][Full Text] [Related]
20. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Brandl C; Haas C; d'Argouges S; Fisch T; Kufer P; Brischwein K; Prang N; Bargou R; Suzich J; Baeuerle PA; Hofmeister R Cancer Immunol Immunother; 2007 Oct; 56(10):1551-63. PubMed ID: 17310380 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]